Novadip Biosciences, a Belgian biotech company specializing in regenerative bone therapies, has closed a €10.4 million convertible financing round to accelerate development of its lead candidate for a rare pediatric bone condition.
The financing round, led by New Science Ventures, brings together a diverse investor consortium including Fund+, Wallonie Entreprendre, VIVES Fund, ORSA Tech, Sambrinvest, Noshaq, and Invest.BW. The capital injection not only advances Novadip’s clinical pipeline but also unlocks access to an €18 million venture debt tranche from the European Investment Bank, providing additional financial resources for regulatory advancement and commercialization planning.
Founded in 2013, Novadip has now accumulated €137 million in total funding since inception, positioning itself as a mature clinical-stage player in the European biotech landscape. The company focuses on autologous cell therapies designed to regenerate bone tissue, addressing conditions where conventional treatments prove insufficient.
Pivotal Trial Advancement
The primary use of the newly raised capital centers on completing a pivotal Phase 3 trial of NVD003, Novadip’s autologous graft therapy targeting congenital pseudarthrosis of the tibia, a rare genetic disorder affecting bone healing in children. The condition causes bones to fail to fuse properly, leading to chronic nonunion and significant morbidity if left untreated.
Beyond clinical development, Novadip plans to leverage the financing to prepare regulatory submissions for the United States market. The company is also pursuing a Rare Pediatric Disease Priority Review Voucher, a regulatory incentive that could accelerate FDA review timelines upon approval of a rare pediatric disease treatment.
Strategic Momentum
Dr. Denis Dufrane, company leadership, emphasized the significance of the financing: “This financing is a strong vote of confidence from our investors, and I’d like to thank them for their ongoing support. This is an important step forward for Novadip. It provides the resources to advance NVD003 through several major clinical and regulatory milestones, including the completion of our pivotal Phase 3 program in congenital pseudarthrosis of the tibia and the preparation for regulatory submission in the United States.”
The financing round represents a strategic inflection point for the company, enabling progression toward regulatory approval while simultaneously strengthening its balance sheet through the combination of equity and debt financing structures.
Broader Ecosystem Context
Novadip’s capital raise underscores the continued strength of Belgian biotech innovation, particularly in specialized therapeutic areas like regenerative medicine. The involvement of multiple regional and specialized investors—including entities like Wallonie Entreprendre and the VIVES Fund—demonstrates how European venture capital ecosystems support late-stage clinical development. The EIB tranche additionally reflects growing institutional confidence in European biotech companies progressing through advanced clinical stages, as development-stage financing increasingly incorporates both traditional equity and debt instruments to optimize capital efficiency during costly Phase 3 trial execution.